A Phase 3 interventional study of Idarucizumab in Hemorrhage, sponsored by Boehringer Ingelheim. Completed at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Hemorrhage with a site in China — 27 open to participants now, 29 under way, 5 of them phase 3. Hemorrhage · China.
Among the 97 studies in Hemorrhage with a site in China, this one is the 74th largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2018, is one of 17 in phase 3, and was the 37th registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →27 of the 97 studies in Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–80
Sun Yat-sen University · Sites in China
Ages 18–75
Guangdong Provincial People's Hospital · Sites in China
Ages 75+
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Jilin University · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 17 · Phase 4 14
First in 2003; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 200 across the 77 interventional studies, 341 across the 20 observational. Of the 39 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 97 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 8 studies filed under Hemorrhage — fewer than ten, so there is no comparison to draw.
11 of the studies in Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129031Phase 3Xijing HospitalOptimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock | 2027-06-30 |
| NCT05764356Peking University First HospitalImapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II | 2026-12 |
| NCT07617428Lanzhou University Second HospitalClinical Validation of a Blood Loss Monitoring System | 2026-12-30 |
| NCT07653945First Affiliated Hospital of Ningbo UniversityRed Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility | 2026-12-31 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 97 studies in Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding requiring urgent intervention, and in patients treated with dabigatran etexilate who require emergency surgery or other invasive procedure.
The secondary objectives are to assess the reduction or cessation of bleeding, evaluate the clinical outcomes, safety and the pharmacokinetics of dabigatran in the presence of idarucizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
They meet the following criteria:
Exclusion criteria:
Group A:
Group B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Idarucizumab
Drug: Idarucizumab
Intravenous
Also known as: PRAXBIND, Praxbind, Prizbind
Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time
Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of ecarin clotting time is reported. The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 41.26 seconds.
Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin Time
Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time is reported. The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 35.54 seconds.
Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Percentage of Participants Achieving Cessation of Bleeding Within 24 Hours After Completion of Second Infusion (for Group A Only)
Percentage of participants achieving cessation of bleeding within 24 hours after completion of second infusion for Group A is reported.
Time frame: Up to 24 hours after the completion of the second infusion on Day 1 of the treatment period.
Number of Participants With Major Bleeding (for Group B Only) Intra-operatively and up to 24 Hours Post-surgery
Number of participants with major bleeding (for Group B only) intra-operatively and up to 24 hours post-surgery per International Society for Thrombosis and Hemostasis (ISTH) classification is reported.
Time frame: Up to 24 hours post-surgery.
Minimum Unbound Sum Dabigatran Concentrations Since the End of First Infusion up to 4 Hours After the Completion of the Last Infusion (Cmin,1)
Minimum unbound sum dabigatran concentrations since the end of first infusion up to 4 hours after the completion of the last infusion (Cmin,1) is reported.
Time frame: Just prior to the second infusion (last infusion) and 10 minutes (min), 30 min, 1 hour (h), 2 h, and 4 h after the end of the second infusion.
Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT)
Maximum reversal of anticoagulation as measured by activated partial thromboplastin time (aPTT) is reported. The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 39.80 seconds.
Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Maximum Reversal of Anticoagulation as Measured by Thrombin Time (TT)
Maximum reversal of anticoagulation as measured by thrombin time (TT) is reported. The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If calculated reversal is \> 100, it was set to 100. 100% ULN is 14.22 seconds.
Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Numbers of Participants With Any Adverse Events - on Treatment
Numbers of participants with any adverse events during on treatment period is reported.
Time frame: Since the first infusion up until 5 days after the completion of the second infusion.
Numbers of Participants With Any Adverse Events - Including Post Treatment Period
Numbers of participants with any adverse events until end of study is reported.
Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Number of Participants With Serious Adverse Events - on Treatment
Number of participants with Serious adverse events during on treatment period is reported.
Time frame: Since the first infusion up until 5 days after the completion of the second infusion.
Number of Participants With Serious Adverse Events - Including Post Treatment Period
Number of participants with Serious adverse events until the end of study is reported.
Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Number of Participants With Drug-related Adverse Events - on Treatment
Numbers of patients with drug-related adverse events during on treatment period is reported.
Time frame: Since the first infusion up until 5 days after the completion of the second infusion.
Number of Participants With Drug-related Adverse Events - Including Post Treatment Period
Numbers of patients with drug-related adverse events until end of study is reported.
Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Number of Participants With Immune Reaction Adverse Event - on Treatment
Number of participants with immune reaction adverse event during on treatment period is reported.
Time frame: Since the first infusion up until 5 days after the completion of the second infusion.
Number of Participants With Immune Reaction Adverse Event - Including Post Treatment Period
Number of participants with immune reaction adverse event until end of study is reported.
Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Number of Participants With Thrombotic Events - on Treatment
Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) during on treatment period is reported.
Time frame: Since the first infusion up until 5 days after the completion of the second infusion.
Number of Participants With Thrombotic Events - Including Post Treatment Period
Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) until end of study is reported.
Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
This study was to demonstrate the reversal of the anticoagulant effects of dabigatran by intravenous administration of idarucizumab in patients treated with dabigatran etexilate who had uncontrolled bleeding or required emergency surgery or procedures over treatment period of 1 day following by 30 days follow-up.
| Milestone | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Started | 13 | 6 |
| Completed | 12 | 4 |
| Not completed | 1 | 2 |
| Withdrew: Refused to complete follow up | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Reluctant to collect blood and received telephone follow up | 1 | 0 |
Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of ecarin clotting time is reported. The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 41.26 seconds.
| Percentage | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure | Total |
|---|---|---|---|
| Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time | 100.0 (100.0 to 100.0) | 100.0 (96.8 to 100.0) | 100.0 (100.0 to 100.0) |
Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time is reported. The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 35.54 seconds.
| Percentage | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure | Total |
|---|---|---|---|
| Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin Time | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
Percentage of participants achieving cessation of bleeding within 24 hours after completion of second infusion for Group A is reported.
| Percentage of participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding |
|---|---|
| Percentage of Participants Achieving Cessation of Bleeding Within 24 Hours After Completion of Second Infusion (for Group A Only) | 55.6 |
Number of participants with major bleeding (for Group B only) intra-operatively and up to 24 hours post-surgery per International Society for Thrombosis and Hemostasis (ISTH) classification is reported.
| Participants | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|
| Minor | 0 |
| Major | 1 |
| Major, Life -Threatening or Fatal | 0 |
| Not assessable | 0 |
Minimum unbound sum dabigatran concentrations since the end of first infusion up to 4 hours after the completion of the last infusion (Cmin,1) is reported.
| nanogram per milliliter | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Minimum Unbound Sum Dabigatran Concentrations Since the End of First Infusion up to 4 Hours After the Completion of the Last Infusion (Cmin,1) | 1 ± 0 | 1 ± 0 |
Maximum reversal of anticoagulation as measured by activated partial thromboplastin time (aPTT) is reported. The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 39.80 seconds.
| Percentage | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure | Total |
|---|---|---|---|
| Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT) | 100 (67.9 to 100.0) | 100 (98.3 to 100.0) | 100 (98.3 to 100.0) |
Maximum reversal of anticoagulation as measured by thrombin time (TT) is reported. The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If calculated reversal is \> 100, it was set to 100. 100% ULN is 14.22 seconds.
| Percentage | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure | Total |
|---|---|---|---|
| Maximum Reversal of Anticoagulation as Measured by Thrombin Time (TT) | 100 (100.0 to 100.0) | 100 (100.0 to 100.0) | 100 (100.0 to 100.0) |
Numbers of participants with any adverse events during on treatment period is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Numbers of Participants With Any Adverse Events - on Treatment | 11 | 6 |
Numbers of participants with any adverse events until end of study is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Numbers of Participants With Any Adverse Events - Including Post Treatment Period | 13 | 6 |
Number of participants with Serious adverse events during on treatment period is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Number of Participants With Serious Adverse Events - on Treatment | 3 | 1 |
Number of participants with Serious adverse events until the end of study is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Number of Participants With Serious Adverse Events - Including Post Treatment Period | 7 | 3 |
Numbers of patients with drug-related adverse events during on treatment period is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Number of Participants With Drug-related Adverse Events - on Treatment | 2 | 1 |
Numbers of patients with drug-related adverse events until end of study is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Number of Participants With Drug-related Adverse Events - Including Post Treatment Period | 2 | 1 |
Number of participants with immune reaction adverse event during on treatment period is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Number of Participants With Immune Reaction Adverse Event - on Treatment | 3 | 0 |
Number of participants with immune reaction adverse event until end of study is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Number of Participants With Immune Reaction Adverse Event - Including Post Treatment Period | 3 | 0 |
Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) during on treatment period is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Number of Participants With Thrombotic Events - on Treatment | 1 | 1 |
Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) until end of study is reported.
| Participants | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| Number of Participants With Thrombotic Events - Including Post Treatment Period | 2 | 3 |
Collected over Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A - Patients With Uncontrolled or Life-threatening Bleeding | 0/13 (0%) | 7/13 (53.8%) | 13/13 (100%) |
| Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Event | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/13 | 1/6 |
| Cardiac failureCardiac disorders | 0/13 | 1/6 |
| Cardiac failure chronicCardiac disorders | 0/13 | 1/6 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/13 | 1/6 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/13 | 1/6 |
| Hepatic function abnormalHepatobiliary disorders | 0/13 | 1/6 |
| PneumoniaInfections and infestations | 1/13 | 1/6 |
| SeizureNervous system disorders | 0/13 | 1/6 |
| Thalamic infarctionNervous system disorders | 0/13 | 1/6 |
| DeliriumPsychiatric disorders | 2/13 | 0/6 |
| Event | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/13 | 3/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/13 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 2/13 | 2/6 |
| InfectionInfections and infestations | 2/13 | 2/6 |
| Neutrophil percentage increasedInvestigations | 0/13 | 2/6 |
| White blood cell count increasedInvestigations | 0/13 | 2/6 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 3/13 | 2/6 |
| ConstipationGastrointestinal disorders | 4/13 | 0/6 |
| PyrexiaGeneral disorders | 3/13 | 0/6 |
| HypokalaemiaMetabolism and nutrition disorders | 3/13 | 0/6 |
Treated set (TS): include all patients who are administered with idarucizumab.
| Age, Continuous(Years) | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure | Total |
|---|---|---|---|
| Mean | 75.4 ± 12.3 | 62.8 ± 10.6 | 71.4 ± 13.0 |
| Sex: Female, Male(Participants) | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 8 | 2 | 10 |
| Race (NIH/OMB)(Participants) | Group A - Patients With Uncontrolled or Life-threatening Bleeding | Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 13 | 6 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Mar 2018 to primary completion in Jul 2020, 27 months.
Results were first posted in Aug 2021, 1 year 1 month after primary completion.
Of 72 phase 3 interventional studies under Hemorrhage, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idarucizumab